Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Withdrawn 1Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Propranolol × Genitourinary × Clear all
NCT03152786 2025-02-17

Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Wake Forest University Health Sciences

Phase 2 Terminated
46 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT01857817 2018-04-26

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Vicus Therapeutics

Phase 2 Terminated
35 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡